Selling by month
Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
No plan disclosedOne dollar scale for every month; the tallest bar is labeled
Pattern
What the filings show, past 12 months. Nothing here rates or predicts.
- Sold in 2 of the 13 calendar months from Oct 2025 to Oct 2026: Oct 2025 and Feb 2026.
- Largest single sale: $7.3M (29,927 shares) of Johnson & Johnson on Feb 17, 2026. Filing
- Last sale before this period: Jul 17, 2025.
Roles from filings
Every company we track where this person has filed, newest filing first.
| Company | Title | First filing | Latest filing |
|---|---|---|---|
| Madrigal Pharmaceuticals, Inc. (MDGL) | Director | Aug 18, 2026 | Aug 18, 2026 |
| Johnson & Johnson (JNJ) | EVP, Innovative Medicine, R&D | Apr 13, 2023 | May 4, 2026 |
| Ionis Pharmaceuticals Inc (IONS) | Former Director | Jul 2, 2004 | Sep 6, 2012 |
Also a director at
Ionis Pharmaceuticals Inc (IONS) (no filing in the last 18 months)
Recent filings
The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.
- Aug 15, 2026, Madrigal Pharmaceuticals, Inc.: 647 shares granted. 1 filing: 1
- May 1, 2026, Johnson & Johnson: 25,255 shares vested; 11,002 shares withheld by the company for taxes. 1 filing: 1
- Feb 17, 2026, Johnson & Johnson: sold 53,931 shares for $13.1M, no plan disclosed; 51,648 shares acquired by exercising options. 1 filing: 1
- Feb 15, 2026, Johnson & Johnson: 3,196 shares vested; 913 shares withheld by the company for taxes. 1 filing: 1
- Oct 17, 2025, Johnson & Johnson: sold 21,721 shares for $4.2M, no plan disclosed; 21,721 shares acquired by exercising options. 1 filing: 1
This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.